aBLA Filing Intelligence & Biosimilar Opportunity

Tezspire

Tezepelumab-Ekko

Respiratory agents

Subcutaneous Solution

Approval Date

17-Dec-21

Data Exclusivity Expiry

17-Dec-25

Market Exclusivity Expiry

17-Dec-33

Commercial snapshot

Market performance & projections

Revenue ($M)

2609

CAGR (%)

0.2222

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

3722

2027

4548

2028

5256

2029

5822

2030

6415

2031

6996

2032

7494

Molecule profile

Details & specifications

Molecule

Tezepelumab-Ekko

Innovator

AMGEN INC

Dosage Form

Subcutaneous Solution

Strength

210 mg/1.91 mL (110 mg/mL)

Therapeutic Category

Respiratory agents

Usage

To treat severe asthma as an add-on maintenance therapy

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.